Understanding the interaction between the intestinal microbiome and cancer immunotherapy may lead to better approaches for cancer treatment.
Yasser Heakal, PhD, MS, MBA, RPh
Advertisement
Yasser Heakal, PhD, MS, MBA, RPh, is an Assistant Professor of Pharmacology at D'Youville College School of Pharmacy in Buffalo, New York. He received his MBA and PhD in pharmacology from Pennsylvania State University and then completed a research fellowship in translational cancer research, as well as a pharmacy internship at the University of North Carolina Lineberger Comprehensive Cancer Center. His current interests are focused on applications of pharmacogenomics in clinical practice.
Articles by Yasser Heakal, PhD, MS, MBA, RPh
Advertisement
Latest Updated Articles
- Could the Human Microbiome Hold the Key to Precision Cancer Immunotherapy?
Published: November 9th 2016 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Grants Interchangeability Designation to Denosumab Biosimilars Stoboclo and Osenvelt
2
Because Ned Said: America’s Growing Pharmacy Deserts Are Leaving Patients High and Dry
3
Denosumab Biosimilars Conexxence and Bomyntra Receive Interchangeability Designation
4
Meeting Patients Where They Are: How Pharmacists Are Helping People Stay on Track With Schizophrenia Treatment
5
